Antigen binding molecules that bind EGFR, vectors encoding...

Details Antigen binding molecules that bind EGFR, vectors encoding... Antigen binding molecules that bind EGFR, vectors encoding...

2007-08-09

2010-02-16

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S143100, C424S185100, C435S069100, C435S326000, C530S387300, C530S388150, C530S388220

Reexamination Certificate

active

07662377

ABSTRACT:
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6602684 (2003-08-01), Umaña et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6737056 (2004-05-01), Presta
patent: 6815184 (2004-11-01), Stomp et al.
patent: 2001/0049105 (2001-12-01), Singh et al.
patent: 2002/0128448 (2002-09-01), Reff
patent: 2003/0039649 (2003-02-01), Foote
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0115614 (2003-06-01), Kanda et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0175269 (2003-09-01), Black et al.
patent: 2003/0175884 (2003-09-01), Umaña et al.
patent: 2003/0190689 (2003-10-01), Crosby et al.
patent: 2004/0072290 (2004-04-01), Umaña et al.
patent: 2004/0093621 (2004-05-01), Shitara et al.
patent: 2004/0110282 (2004-06-01), Kanda et al.
patent: 2004/0110704 (2004-06-01), Yamane et al.
patent: 2004/0132066 (2004-07-01), Balint et al.
patent: 2004/0132097 (2004-07-01), Bacus et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0132140 (2004-07-01), Satoh et al.
patent: 2004/0241817 (2004-12-01), Umaña et al.
patent: 2005/0074843 (2005-04-01), Umaña et al.
patent: 2005/0079605 (2005-04-01), Umaña et al.
patent: 2005/0123546 (2005-06-01), Umaña et al.
patent: 2005/0272128 (2005-12-01), Umaña et al.
patent: 2006/0269545 (2006-11-01), Umaña et al.
patent: 1 176 195 (2002-01-01), None
patent: WO 95/20045 (1995-07-01), None
patent: WO 99/54342 (1999-10-01), None
patent: WO 03/056914 (2003-07-01), None
patent: WO 03/078614 (2003-09-01), None
patent: WO 03/084570 (2003-10-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 2004/024927 (2004-03-01), None
patent: WO 2004/057002 (2004-07-01), None
patent: WO 2004/063351 (2004-07-01), None
patent: WO 2004/065540 (2004-08-01), None
patent: WO 2004/065540 (2004-08-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/056606 (2005-06-01), None
patent: WO 2005/056759 (2005-06-01), None
patent: WO 2007/031875 (2007-03-01), None
Rudikoff et al, Proc Natl Acad Sci USA vol. 79 pp. 1979-1983, 1982.
Kobrin et al, J Immunology 146: 2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Shields et al, J Biol Chem 277(30): 26733-26740, 2002.
Mariuzza et al, Annu. Rev. Biophys. Biophys. Chem 16: 139-159, 1987.
G0ssow et al, Methods in Enzymology 203: 99-121, 1991.
Giusti et al, Proc. Natl. Acad. Sci. USA. 84 (9): 2926-2930, May 1987.
Chien et al, Proc. Natl. Acad. Sci USA. 86 (14): 5532-5536, Jul. 1989.
Caldes et al, Mol. Immunol. 39 (15): 941-952, May 2003.
Vajdos et al, J. Mol. Biol. 320 (2): 415-428, Jul. 2002.
Andersen, D.C. and Krummen, L., “Recombinant protein expression for therapeutic applications,”Curr. Opin. Biotechnol. 13:117-123, Elsevier Science Ltd. (2002).
Appelbaum, F.R., “Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma,”Hematol./Oncol. Clin. N. Am. 5:1013-1025, W.B. Saunders (1991).
Atalay, G., et al., “Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer,”Ann. Oncol. 14:1346-1363, Oxford University Press (2003).
Becker, J., “Signal transduction inhibitors—a work in progress,”Nat. Biotechnol. 22:15-18, Nature America Publishing (Jan. 2004).
Bier, H., et al., “Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma,”Eur. Arch. Otorhinolaryngol. 252:433-439, Springer-Verlag (1995).
Borth, N., et al., “Efficient Selection of High-Producing Subclones During Gene Amplification of Recombinant Chinese Hamster Ovary Cells by Flow Cytometry and Cell Sorting,”Biotechnol. Bioeng. 71:266-273, John Wiley & Sons, Inc. (2001).
Boulianne, G.L., et al., “Production of functional chimaeric mouse/human antibody,”Nature 312:643-646, Macmillan Journals Ltd. (1984).
Bowie, J.U., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-1310, American Association for the Advancement of Science (1990).
Carter, P., et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA 89:4285-4289, National Academy of Sciences (1992).
Cartron, G., et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene,”Blood 99:754-758, American Society of Hematology (2002).
Chadd, H.E. and Chamow, S.M., “Therapeutic antibody expression technology,”Curr. Opin. Biotechnol. 12:188-194, Elsevier Science Ltd. (2001).
Chothia, C., et al., “Structural Repertoire of the Human VHSegments,”J. Mol. Biol. 227:799-817, Academic Press Limited (1992).
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins, ”J. Mol. Biol. 196:901-917, Academic Press Limited (1987).
Clynes, R.A., et al., “Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets,”Nat. Med. 6:443-446, Nature Publishing Company (2000).
Colbère-Garapin, F., et al., “A New Dominant Hybrid Selective Marker for Higher, Eukaryotic Cells,”J. Mol. Biol. 150:1-14, Academic Press Inc. (London) Ltd. (1981).
Cumming, D.A., “Glycosylation of recombinant protein therapeutics: control and functional implications,”Glycobiology 1:115-130, Oxford University Press (1991).
Davies, J., et al., “Expression of GnTIII in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Anitbodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for FcγRIII,”Biotechnol. Bioeng. 74:288-294, John Wiley & Sons, Inc. (2001).
Deo, Y.M., et al., “Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies,”Immunol. Today 18:127-135, Elsevier Science Ltd. (1997).
Dickson, S., “Scientists Produce Chimeric Monoclonal Abs,”Genetic Eng. News5:1 and 33, Mary Ann Liebert, Inc. (1985).
Dillman, R.O., “Magic Bullets at Last! Finally-Approval of a Monoclonal Antibody for the Treatment of Cancer!!!,”Cancer Biother. Radiopharm. 12:223-225, Mary Ann Liebert, Inc. (1997).
Eary, J.F., et al., “Imaging and Treatment of B-Cell Lymphoma,”J. Nucl. Med. 31:1257-1268, Society of Nuclear Medicine (1990).
Ferrara, C., et al., “The Carbohydrate at FcγRIIIa Asn-162. An Element Required for High Affinity Binding to Non-Fucosylated IgG Glycoforms,”J. Biol. Chem. 281:5032-5036, American Society for Biochemistry and Molecular Biology, Inc. (Feb. 2006).
Frost, J.D., et al., “A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 in Children with Refractory Neuroblastoma,”Cancer 80:317-333, John Wiley & Sons, Inc. (1997).
Gadella, T.W.J. and Jovin, T.M., “Oligomerization of Epidermal Growth Factor Receptors on A431 Cells Studie

Affiliated with

Also associated with

Rating

Antigen binding molecules that bind EGFR, vectors encoding... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen binding molecules that bind EGFR, vectors encoding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding molecules that bind EGFR, vectors encoding... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4229126